Almirall stock advances on its dermatology pipeline and 2025 results
Published on 07/21/2026 at 14:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Almirall (ES0157097017) is trading against a 2025 backdrop that included EUR 990.6 million in net sales, EUR 204.6 million in EBITDA and EUR 202.6 million in net profit, with the latest investor-relations material setting the operating baseline for 2026. The company also reported that its dermatology focus remains central to the group, which makes product-level execution and margin delivery the key investor variables.
2025 numbers set the base
For the full year 2025, Almirall reported net sales of EUR 990.6 million, EBITDA of EUR 204.6 million and net profit of EUR 202.6 million. Those figures define the starting point for the stock because they show a business with meaningful earnings capacity rather than a pure growth story.
The comparison also matters: the net sales base of EUR 990.6 million and EBITDA of EUR 204.6 million give investors a concrete yardstick for any 2026 update, while the EUR 202.6 million net profit shows that the company ended the year with a positive bottom line.
Margin and profit matter
Almirall stock is therefore likely to stay sensitive to the next reported shift in sales mix, operating margin and profit conversion. If the company can keep EBITDA near the EUR 204.6 million level from 2025, the market will treat that as evidence that the core dermatology portfolio is still carrying the group.
The same logic applies to revenue development. A move away from the EUR 990.6 million sales base would be read against the 2025 benchmark, not in isolation, because the most useful question for shareholders is whether earnings quality is improving faster than turnover.
Dermatology remains central
Almirall's product focus is dermatology, and that is the right lens for judging the stock because the group has built its profile around branded treatments and specialist care. The business model is narrower than a diversified pharma peer, which increases the importance of execution in the core franchise.
That also means that product performance can matter more than broad sector headlines. A stable dermatology base gives the company room to defend margins, but the 2025 numbers show that the market already has a profit-led reference point to compare with any later update.
2025 is the reference year
The key comparison is straightforward: EUR 990.6 million in sales, EUR 204.6 million in EBITDA and EUR 202.6 million in net profit form the reference set for 2026. Those three numbers matter because they are dated, concrete and directly tied to the company rather than to a generic sector trend.
That makes the stock less about narrative and more about whether the next operating update can defend or improve on the 2025 base. For investors, the margin path will matter more than broad market language.
Almirall dermatology products
Almirall's dermatology portfolio is the business line most likely to influence the next market read-through. In practical terms, the share price tends to react to whether the company can extend the commercial life of its core treatments and keep earnings moving in the right direction.
Almirall stock at a glance
Almirall stock can be framed from the 2025 results alone: EUR 990.6 million in net sales, EUR 204.6 million in EBITDA and EUR 202.6 million in net profit. Those are the numbers that matter most for the current valuation discussion and for any later comparison with 2026 performance.
Almirall at a glance
- Company: Almirall, S.A.
- ISIN: ES0157097017
- Ticker: BME: ALM
- Trading venue: Bolsa de Madrid
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: IBEX 35
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
